Newsroom

Press Release - All

• 14 Jul 2026
  Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
• 08 Jul 2026
  Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
• 01 Jul 2026
  Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
• 25 Jun 2026
  Agilent Completes Acquisition of Biocare Medical
• 03 Jun 2026
  Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
• 02 Jun 2026
  Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
• 01 Jun 2026
  Agilent and Sound Analytics Collaborate to Advance LC/MS Workflows for Drug Metabolism Research
• 29 May 2026
  Agilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026
• 28 May 2026
  Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
• 27 May 2026
  Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results